Differential persistence of transmitted HIV-1 drug resistance mutation classes. - Wikidata - awgldk - TriplyDB

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

http://www.wikidata.org/entity/Q35022802

about

Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection Patterns of transmitted HIV drug resistance in Europe vary by risk group Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study HIV-1 drug resistance and resistance testing.Association of Change of Anthropometric Measurements With Incident Type 2 Diabetes Mellitus: A Pooled Analysis of the Prospective Population-Based CARLA and SHIP Cohort Studies.Association of neighbourhood unemployment rate with incident Type 2 diabetes mellitus in five German regions.Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network Community HIV-1 drug resistance is associated with transmitted drug resistance Ten years survey of primary HIV-1 resistance in Serbia: the occurrence of multiclass resistance.The impact of wild-type reversion on transmitted resistance surveillance.Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance.Prevalence of transmitted HIV-1 antiretroviral resistance among patients initiating antiretroviral therapy in Brazil: a surveillance study using dried blood spots.HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.HIV-1 antiretroviral resistance: scientific principles and clinical applications Transmitted antiretroviral drug resistance in the men who have sex with men HIV patient cohort, Beijing, China, 2008-2011 Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S.HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response.Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients.Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013.Anthropometric markers and their association with incident type 2 diabetes mellitus: which marker is best for prediction? Pooled analysis of four German population-based cohort studies and comparison with a nationwide cohort study.High prevalence of PI resistance in patients failing second-line ART in Vietnam.Clinical implications of HIV-1 minority variants Response to Therapy in Antiretroviral Therapy-Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor-Associated Transmitted Drug Resistance The role of backward mutations on the within-host dynamics of HIV-1.Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa.Persistence of HIV-1 transmitted drug resistance mutations.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel Estimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains.

P2860

Q28477624-918303D3-D8D7-4ADA-9930-FAF4825B30A1 Q28478459-B39D1125-9D85-4D5D-BF5B-FB85E3C561A5 Q28537726-3C5D1ED9-6EEB-4AA2-A08B-9149D60E40AA Q28544845-A9CB6571-9B50-42E4-9992-7DFFFC7856B5 Q28545866-DD31611F-0B8D-48FE-A7E3-CE5450740B0B Q28550907-3D998A85-CA9F-4570-BDD8-30EC91520D76 Q28552455-34731817-2053-42ED-999C-FEBB938CE305 Q28728325-B437C82C-6A03-4F54-93C5-50F7CF554543 Q30245693-DC2A3255-EA03-48ED-9BDC-B68CAEDB3EDA Q30316235-688C44BA-FC37-4360-BA97-8E1F0A8F0ACB Q30316952-F9380AFB-F9C3-455B-90D1-F4E85C0000A8 Q33589187-38CE71E4-2287-42C4-A6A2-9D0309F6AACB Q33748960-2EA598AB-D5E1-43D4-90EC-CCD485D70FBD Q33828355-72957593-B454-41DC-BC9F-6A018F5BDE92 Q34054047-8A7D2263-5A67-45B7-933F-D42E6F075B13 Q34195115-83C1D4BA-3844-4679-A292-0E7B1BB73482 Q34232916-2615D741-E7B1-4132-A253-2A93C1277961 Q34249966-DB89F8EB-1F72-4A5A-B211-0C8D36A511BD Q34280466-F952BA3D-E275-4566-99A5-FC9BC3855ADE Q34283967-B99E04AB-CB2C-41F6-992F-FC9770D514AC Q34469240-4D92DDE9-D1D2-47B2-880C-B2163ACAF718 Q34677368-5C638339-20E6-4E7B-9254-588C425224EB Q35079169-8106565B-A05C-44E4-803F-78AC721F5FDA Q35943486-19A57EC3-1D35-4E5F-8AC1-F816BD7EB050 Q35993707-314D25F0-04E4-4561-B995-9C7CD9574A69 Q36050107-72E463F1-93CA-4209-B401-F4E294826B0D Q36053733-A609128B-652A-4506-B28C-F98CD46B4718 Q36255602-7DFE65AC-2FE0-4520-984D-9FAF39875DFA Q36274049-7DD038DA-3A5C-4D6F-8A7D-5B62D8F30DD2 Q36279238-733ADB97-7E60-4EE9-A1C9-DA0B19B777AD Q36460056-4FD4E167-ECDE-4A64-9E2D-29D341FE60E0 Q36527218-A86733BA-70C9-4AC1-8309-5BE6FE4A8138 Q36551309-8A5FAF48-5C31-43DE-B9C7-DC41C9908159 Q36811249-93385602-D250-4B52-832E-AFE52B17DF26 Q36900951-E639ABDB-D6FE-44AC-8474-B2BBA09DE41D Q37007926-02D4544B-08A5-44F4-BAE3-504D48B0AD02 Q37140535-49A38523-1313-40DF-B348-ADBE1A0D5989 Q37213028-D0D850AA-50F6-4C5C-B0EF-04CA067F1B3A Q37234729-9F479144-B3EB-4E1D-8664-AB5DCA911113 Q37447287-49F4C5BA-3C56-4EF7-9CCF-277F4BF7E923

P2860

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

http://www.wikidata.org/entity/Q35022802

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

@ast

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

@en

type

label

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

@ast

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

@en

prefLabel

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

@ast

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

@en

P1433

Q35022802-42D60245-FDC2-460F-B6C4-31B0FA850F3A

P1476

Q35022802-D62A892D-338F-4123-95F3-9EE03F4FCB95

P2093

Q35022802-2280638E-7C92-42B8-87F4-4C53E8360C09

Q35022802-71E4668E-66DB-4072-A21B-79B9B759223D

Q35022802-7FA846E8-1F22-4977-ADA2-D2110A690DE6

Q35022802-9BAB5906-8AC7-4F4D-B59D-405477E386C6

Q35022802-9E3DFEC1-C587-4298-BA11-3D06DC0DE3A2

Q35022802-ABC21E42-718E-4F1E-A7BB-B9B940464C36

Q35022802-AC3D9634-EA53-48F8-8B6C-880FE86E6162

Q35022802-DF817229-955D-4BA1-831B-11BFFD47FCBA

Q35022802-F68AC07C-ED7D-4822-BE81-3163490F882F

P2860

Q35022802-036468CD-7EE7-445B-AED2-3244AAE2BCFE

Q35022802-08C4D404-2AEB-4C5E-9143-8ECE96220A18

Q35022802-0B4DF4D8-7F60-44E0-A0BA-0B7119EE90A7

Q35022802-0D3EEB2E-4822-4A5B-8A1A-195A585A5D1C

Q35022802-0EB0045D-1676-40AF-9C7E-9968B84F308D

Q35022802-1071EF58-CBF2-41F4-98B9-CB1A2B134775

Q35022802-180D4FEF-77F6-4CDB-8808-AB3904095A73

Q35022802-1B0AE862-E3B6-4BEE-96D5-98623B501C2F

Q35022802-1BE87916-8EAA-44F1-89A6-E60B4BD05E36

Q35022802-253745D7-8AB6-4D89-971D-CE4A052C6878

P304

Q35022802-75F16EFA-BE2C-4503-A8FA-22FB8FFC963D

P31

Q35022802-059A85BF-8ECB-48FE-9DD1-6DD26E5A3F43

P356

Q35022802-4346FE73-247B-4255-A470-F57E6A10B83B

P407

Q35022802-E9C12F21-1821-401E-885B-109705839ACA

P433

Q35022802-380E1E35-ED63-42F2-8554-8BA7736732E2

P478

Q35022802-D6E626D2-2641-4994-9D6C-8A5C173C6548

P50

Q35022802-3CC179B2-8328-4C5E-9ABB-5EEC352FCE08

Q35022802-5E04F39D-0672-40BD-AF0C-9982E2C8A4CF

Q35022802-80C517BC-C9CF-4662-8F83-D341E3A8A30B

Q35022802-A4C33306-1C82-4CD8-9DD0-4C348B8C0656

P577

Q35022802-21C42B45-4800-44EE-BFFB-6FB63B359218

P5875

Q35022802-4E88BFF2-827D-43DE-B847-C403EE52902C

P698

Q35022802-54CAE0A3-845A-40D6-8C33-14DB8097E503

P921

Q35022802-D294B6A6-F3B6-4798-B9F4-93C8F5DE2C5E

P932

Q35022802-EDA325AF-4957-4AE4-BBF6-59EF791E6FBD

P356

P1433

The Journal of Infectious Diseases

P1476

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

@en

P2093

Christopher D Pilcher

http://www.w3.org/2001/XMLSchema#string

Luiz M Janini

http://www.w3.org/2001/XMLSchema#string

Maria C Sucupira

http://www.w3.org/2001/XMLSchema#string

Peter Bacchetti

http://www.w3.org/2001/XMLSchema#string

Ricardo S Diaz

http://www.w3.org/2001/XMLSchema#string

Rodrigo Cortes

http://www.w3.org/2001/XMLSchema#string

Teri Liegler

http://www.w3.org/2001/XMLSchema#string

Vivek Jain

http://www.w3.org/2001/XMLSchema#string

Wendy Hartogensis

http://www.w3.org/2001/XMLSchema#string

P2860

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

Analysis of clustered and interval censored data from a community-based study in asthma.

Parametric survival models for interval-censored data with time-dependent covariates.

Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.

Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.

Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007

Wide variation in the multiplicity of HIV-1 infection among injection drug users

Use of laboratory tests and clinical symptoms for identification of primary HIV infection.

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).

P304

1174-1181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIQ167

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

203

http://www.w3.org/2001/XMLSchema#string

P50

Frederick M. Hecht

Robert M. Grant

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50936466

http://www.w3.org/2001/XMLSchema#string

P698

21451005

http://www.w3.org/2001/XMLSchema#string

P921

HIV transmission

P932

3107558

http://www.w3.org/2001/XMLSchema#string